Gianluca Campo

List of Publications by Year
in descending order

270	12,849	38660 50	29081 104
papers	citations	h-index	g-index

279	279	279	14068
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Reduced Rate of Hospital Admissions for ACS during Covid-19 Outbreak in Northern Italy. New England Journal of Medicine, 2020, 383, 88-89.	13.9	873
2	Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting. Circulation, 2012, 125, 2015-2026.	1.6	640
3	Five-Year Outcomes with PCI Guided by Fractional Flow Reserve. New England Journal of Medicine, 2018, 379, 250-259.	13.9	622
4	Complete Revascularization with Multivessel PCI for Myocardial Infarction. New England Journal of Medicine, 2019, 381, 1411-1421.	13.9	542
5	Short Physical Performance Battery and all-cause mortality: systematic review and meta-analysis. BMC Medicine, 2016, 14, 215.	2.3	534
6	Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet, The, 2019, 394, 1335-1343.	6.3	465
7	Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet, The, 2016, 388, 2479-2491.	6.3	451
8	Prospective Evaluation of On-Clopidogrel Platelet Reactivity Over Time in Patients Treated With Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2011, 57, 2474-2483.	1.2	315
9	Tirofiban and Sirolimus-Eluting Stent vs Abciximab and Bare-Metal Stent for Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2005, 293, 2109.	3.8	290
10	Zotarolimus-Eluting Versus Bare-Metal Stents in Uncertain Drug-Eluting Stent Candidates. Journal of the American College of Cardiology, 2015, 65, 805-815.	1.2	248
11	Comparison of Angioplasty With Infusion of Tirofiban or Abciximab and With Implantation of Sirolimus-Eluting or Uncoated Stents for Acute Myocardial Infarction<subtitle>The MULTISTRATEGY Randomized Trial</subtitle>. JAMA - Journal of the American Medical Association, 2008, 299, 1788.	3.8	245
12	Diagnostic Performance of Inâ€Procedure Angiographyâ€Derived Quantitative Flow Reserve Compared to Pressureâ€Derived Fractional Flow Reserve: The FAVOR II Europeâ€Japan Study. Journal of the American Heart Association, 2018, 7, .	1.6	240
13	Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Lancet, The, 2018, 392, 835-848.	6.3	215
14	Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention. Circulation, 2009, 119, 3215-3222.	1.6	213
15	Molecular identity of the mitochondrial permeability transition pore and its role in ischemia-reperfusion injury. Journal of Molecular and Cellular Cardiology, 2015, 78, 142-153.	0.9	194
16	Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial. Lancet, The, 2016, 387, 357-366.	6.3	174
17	Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets. Lancet, The, 2021, 397, 199-207.	6.3	164
18	Mitochondrial permeability transition involves dissociation of F₁<scp>F_O ATP</scp> synthase dimers and Câ€ring conformation. EMBO Reports, 2017, 18, 1077-1089.	2.0	163

#	Article	IF	Citations
19	Prasugrel Versus Tirofiban Bolus With or Without Short Post-Bolus Infusion With or Without Concomitant Prasugrel Administration in Patients With Myocardial Infarction Undergoing Coronary Stenting. JACC: Cardiovascular Interventions, 2012, 5, 268-277.	1.1	162
20	Value of Platelet Reactivity in Predicting Response to Treatment and Clinical Outcome in Patients Undergoing Primary Coronary Intervention. Journal of the American College of Cardiology, 2006, 48, 2178-2185.	1.2	140
21	Is Bare-Metal Stent Implantation StillÂJustifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?. JACC: Cardiovascular Interventions, 2016, 9, 426-436.	1.1	135
22	Prediction of 1-Year Clinical Outcomes Using the SYNTAX Score in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2011, 4, 66-75.	1.1	132
23	Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management. Journal of the American College of Cardiology, 2017, 69, 2592-2603.	1.2	132
24	Two-Year Outcomes After First- or Second-Generation Drug-Eluting or Bare-Metal Stent Implantation in All-Comer Patients Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2014, 7, 20-28.	1.1	124
25	Transradial Coronary Catheterization and Intervention Across the Whole Spectrum of Allen Test Results. Journal of the American College of Cardiology, 2014, 63, 1833-1841.	1.2	123
26	Long-Term Clinical Outcome Based on Aspirin and Clopidogrel Responsiveness Status After Elective Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2010, 56, 1447-1455.	1.2	118
27	Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. European Heart Journal, 2010, 31, 35-49.	1.0	103
28	Prognostic Value of QFR Measured Immediately After Successful Stent Implantation. JACC: Cardiovascular Interventions, 2019, 12, 2079-2088.	1.1	103
29	Markers of endothelial and epithelial pulmonary injury in mechanically ventilated COVID-19 ICU patients. Critical Care, 2021, 25, 74.	2.5	94
30	Mechanistic Role of mPTP in Ischemia-Reperfusion Injury. Advances in Experimental Medicine and Biology, 2017, 982, 169-189.	0.8	91
31	Chronic Obstructive Pulmonary Disease and Ischemic Heart Disease Comorbidity: Overview of Mechanisms and Clinical Management. Cardiovascular Drugs and Therapy, 2015, 29, 147-157.	1.3	88
32	Impact of COPD on Long-term Outcome After ST-Segment Elevation Myocardial Infarction Receiving Primary Percutaneous Coronary Intervention. Chest, 2013, 144, 750-757.	0.4	86
33	Evolving Routine Standards in InvasiveÂHemodynamic Assessment of Coronary Stenosis. JACC: Cardiovascular Interventions, 2018, 11, 1482-1491.	1.1	85
34	Poor Responsiveness to Clopidogrel: Drug-Specific or Class-Effect Mechanism?. Journal of the American College of Cardiology, 2007, 50, 1132-1137.	1.2	82
35	Quantitative Flow Ratio Identifies Nonculprit Coronary Lesions Requiring Revascularization in Patients With ST-Segmentâ€“Elevation Myocardial Infarction and Multivessel Disease. Circulation: Cardiovascular Interventions, 2018, 11, e006023.	1.4	80
36	Diagnostic performance of quantitative flow ratio in prospectively enrolled patients: An individual patientâ€data metaâ€analysis. Catheterization and Cardiovascular Interventions, 2019, 94, 693-701.	0.7	79

#	Article	IF	Citations
37	Two-Year Clinical Follow-Up After Sirolimus-Eluting Versus Bare-Metal Stent Implantation Assisted by Systematic Glycoprotein IIb/IIIa Inhibitor Infusion in Patients With Myocardial Infarction. Journal of the American College of Cardiology, 2007, 50, 138-145.	1.2	78
38	A Patient-Level Pooled Analysis Assessing the Impact of the SYNTAX (Synergy Between Percutaneous) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Patients Enrolled in Contemporary Coronary Stent Trials. JACC: Cardiovascular Interventions, 2011, 4, 645-653.	1.1	70
39	Cardiac troponin elevation predicts all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: Systematic review and meta-analysis. International Journal of Cardiology, 2015, 191, 187-193.	0.8	69
40	Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 203-210.	1.4	69
41	Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segmentâ€“Elevation Myocardial Infarction. Circulation, 2020, 142, 441-454.	1.6	67
42	Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention. American Heart Journal, 2010, 160, 804-811.	1.2	66
43	Notch Signaling Regulates Immune Responses in Atherosclerosis. Frontiers in Immunology, 2019, 10, 1130.	2.2	63
44	A serum proteome signature to predict mortality in severe COVID-19 patients. Life Science Alliance, 2021, 4, e202101099.	1.3	62
45	Grip strength predicts cardiac adverse events in patients with cardiac disorders: an individual patient pooled meta-analysis. Heart, 2019, 105, 834-841.	1.2	61
46	Complete revascularization reduces cardiovascular death in patients with ST-segment elevation myocardial infarction and multivessel disease: systematic review and meta-analysis of randomized clinical trials. European Heart Journal, 2020, 41, 4103-4110.	1.0	59
47	Short- Versus Long-Term Duration of Dual Antiplatelet Therapy in Patients Treated for In-Stent Restenosis. Journal of the American College of Cardiology, 2014, 63, 506-512.	1.2	58
48	Meta-Analysis of the Duration of Dual Antiplatelet Therapy in Patients Treated With Second-Generation Drug-Eluting Stents. American Journal of Cardiology, 2016, 117, 1714-1723.	0.7	57
49	Tissue Factor and Coagulation Factor VII Levels During Acute Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2800-2806.	1.1	53
50	Poor response to clopidogrel: current and future options for its management. Journal of Thrombosis and Thrombolysis, 2010, 30, 319-331.	1.0	53
51	Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial. American Heart Journal, 2016, 174, 95-102.	1.2	53
52	Radial versus femoral access in patients with acute coronary syndromes with or without ST-segment elevation. European Heart Journal, 2017, 38, 1069-1080.	1.0	52
53	Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease. Thrombosis and Haemostasis, 2017, 117, 1208-1216.	1.8	50
54	The Assessment of Scales of Frailty and Physical Performance Improves Prediction of Major Adverse Cardiac Events in Older Adults with Acute Coronary Syndrome. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 1113-1119.	1.7	49

#	Article	IF	Citations
55	Genetic determinants of on-clopidogrel high platelet reactivity. Platelets, 2011, 22, 399-407.	1.1	48
56	Antiplatelet Treatment Reduces All-Cause Mortality in COPD Patients: A Systematic Review and Meta-Analysis. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2016, 13, 509-514.	0.7	48
57	Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II Trial). EuroIntervention, 2018, 13, 1561-1564.	1.4	45
58	Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: Systematic review and meta-analysis. Chronic Respiratory Disease, 2017, 14, 117-126.	1.0	43
59	SERPINA1 Gene Promoter Is Differentially Methylated in Peripheral Blood Mononuclear Cells of Pregnant Women. Frontiers in Cell and Developmental Biology, 2020, 8, 550543.	1.8	43
60	Reperfusion Damageã€€â€• A Story of Success, Failure, and Hope â€•. Circulation Journal, 2017, 81, 131-141.	0.7	42
61	Prognostic Impact of Hospital Readmissions After Primary Percutaneous Coronary Intervention. Archives of Internal Medicine, 2011, 171, 1948.	4.3	41
62	Discovery of Novel 1,3,8-Triazaspiro[4.5]decane Derivatives That Target the c Subunit of F₁/F_O-Adenosine Triphosphate (ATP) Synthase for the Treatment of Reperfusion Damage in Myocardial Infarction. Journal of Medicinal Chemistry, 2018, 61, 7131-7143.	2.9	41
63	Time course of endothelial dysfunction markers and mortality in COVIDâ€19 patients: A pilot study. Clinical and Translational Medicine, 2021, 11, e283.	1.7	41
64	ACE Inhibition Modulates Endothelial Apoptosis and Renewal via Endothelial Progenitor Cells in Patients with Acute Coronary Syndromes. American Journal of Cardiovascular Drugs, 2011, 11, 189-198.	1.0	40
65	Fractional Flow Reserve Evaluation and Chronic Kidney Disease: Analysis From a Multicenter <scp>I</scp>talian Registry (the <scp>FREAK</scp> Study). Catheterization and Cardiovascular Interventions, 2016, 88, 555-562.	0.7	40
66	Risk of Adverse Cardiac and Bleeding Events Following Cardiac and Noncardiac Surgery in Patients With Coronary Stent. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 39-47.	0.9	40
67	Duration of Dual Antiplatelet Therapy forÂPatients at High Bleeding Risk Undergoing PCI. Journal of the American College of Cardiology, 2021, 78, 2060-2072.	1.2	39
68	The 5-Year Clinical Outcomes After a Randomized Comparison of Sirolimus-Eluting Versus Bare-Metal Stent Implantation in Patients With ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2009, 54, 1900-1901.	1.2	38
69	Mechanisms of Remodelling A Question of Life (Stem Cell Production) and Death (Myocyte Apoptosis). Circulation Journal, 2009, 73, 1973-1982.	0.7	38
70	Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in HeartÂFailure With Reduced Ejection Fraction. JACC: Heart Failure, 2020, 8, 188-198.	1.9	38
71	Exercise intervention improves quality of life in older adults after myocardial infarction: randomised clinical trial. Heart, 2020, 106, 1658-1664.	1.2	37
72	Coronary Artery Surgery Versus Percutaneous Coronary Intervention in Octogenarians: Long-TermÂResults. Annals of Thoracic Surgery, 2015, 99, 567-574.	0.7	36

#	Article	IF	Citations
73	Angio-Based Index of Microcirculatory Resistance for the Assessment of the Coronary Resistance: A Proof of Concept Study. Journal of Interventional Cardiology, 2020, 2020, 1-4.	0.5	36
74	In- and out-of-hospital mortality for myocardial infarction during the first wave of the COVID-19 pandemic in Emilia-Romagna, Italy: A population-based observational study. Lancet Regional Health - Europe, The, 2021, 3, 100055.	3.0	36
75	Nutritional status and all-cause mortality in older adults with acute coronary syndrome. Clinical Nutrition, 2020, 39, 1572-1579.	2.3	35
76	Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials. Clinical Research in Cardiology, 2010, 99, 345-357.	1.5	34
77	Factor XIIIA-V34L and Factor XIIIB-H95R Gene Variants: Effects on Survival in Myocardial Infarction Patients. Molecular Medicine, 2007, 13, 112-120.	1.9	32
78	Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Thrombosis and Haemostasis, 2016, 115, 823-825.	1.8	32
79	Occurrence, causes, and outcome after switching from ticagrelor to clopidogrel in a real-life scenario: data from a prospective registry. Platelets, 2016, 27, 484-487.	1.1	32
80	Bioresorbable Scaffold vs. Second Generation Drug Eluting Stent in Long Coronary Lesions requiring Overlap: A Propensity-Matched Comparison (the UNDERDOGS study). International Journal of Cardiology, 2016, 208, 40-45.	0.8	32
81	Bivalirudin or Heparin in Patients Undergoing Invasive Management of AcuteÂCoronaryÂSyndromes. Journal of the American College of Cardiology, 2018, 71, 1231-1242.	1.2	32
82	Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium. Clinical Pharmacology and Therapeutics, 2020, 108, 1067-1077.	2.3	32
83	10-Year Follow-Up of Patients With Everolimus-Eluting Versus Bare-Metal Stents After ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2021, 77, 1165-1178.	1.2	32
84	Role of the tricuspid regurgitation after mitraclip and transcatheter aortic valve implantation: a systematic review and meta-analysis. European Heart Journal Cardiovascular Imaging, 2018, 19, 654-659.	0.5	31
85	Over time relationship between platelet reactivity, myocardial injury and mortality in patients with SARS-CoV-2-associated respiratory failure. Platelets, 2021, 32, 560-567.	1.1	31
86	Antithrombotic Management and 1-Year Outcome of Patients on Oral Anticoagulation Undergoing Coronary Stent Implantation (from the Registro Regionale Angioplastiche Emilia-Romagna Registry). American Journal of Cardiology, 2012, 109, 1411-1417.	0.7	30
87	Overview of the pharmacological challenges facing physicians in the management of patients with concomitant cardiovascular disease and chronic obstructive pulmonary disease. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 205-211.	1.4	30
88	Platelet aggregation values in patients with cardiovascular risk factors are reduced by verbascoside treatment. A randomized study. Pharmacological Research, 2015, 97, 1-6.	3.1	30
89	The Use of Nutraceuticals to Counteract Atherosclerosis: The Role of the Notch Pathway. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-30.	1.9	30
90	Persistent Coronary No Flow After Wire Insertion Is an Early and Readily Available Mortality Risk Factor Despite Successful Mechanical Intervention in Acute Myocardial Infarction. JACC: Cardiovascular Interventions, 2011, 4, 51-62.	1.1	29

#	Article	IF	Citations
91	Three-year follow-up of the MULTIcentre evaluation of Single high-dose Bolus TiRofiban versus Abciximab with Sirolimus-eluting STEnt or Bare-Metal Stent in Acute Myocardial Infarction StudY (MULTISTRATEGY). International Journal of Cardiology, 2013, 165, 134-141.	0.8	29
92	In Vitro Characterization of Circulating Endothelial Progenitor Cells Isolated from Patients with Acute Coronary Syndrome. PLoS ONE, 2013, 8, e56377.	1.1	29
93	On-treatment platelet reactivity in patients with chronic obstructive pulmonary disease undergoing percutaneous coronary intervention: TableÂ1. Thorax, 2014, 69, 80-81.	2.7	28
94	Full Sternotomy, Hemisternotomy, and Minithoracotomy for Aortic Valve Surgery: Is There a Difference?. Annals of Thoracic Surgery, 2018, 106, 1782-1788.	0.7	28
95	Fo ATP synthase C subunit serum levels in patients with ST-segment Elevation Myocardial Infarction: Preliminary findings. International Journal of Cardiology, 2016, 221, 993-997.	0.8	26
96	Contextâ€dependent function of ROS in the vascular endothelium: The role of the Notch pathway and shear stress. BioFactors, 2017, 43, 475-485.	2.6	26
97	Extracorporeal Circulatory Support in Acute Coronary Syndromes: A Systematic Review and Meta-Analysis. Critical Care Medicine, 2017, 45, e1173-e1183.	0.4	26
98	Exercise Intervention to Improve Functional Capacity in Older Adults After Acute CoronaryÂSyndrome. Journal of the American College of Cardiology, 2019, 74, 2948-2950.	1.2	26
99	Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R). Rationale for the Study and Protocol Design. Cardiovascular Drugs and Therapy, 2008, 22, 313-320.	1.3	25
100	Relationship between Troponin Elevation, Cardiovascular History and Adverse Events in Patients with acute exacerbation of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2015, 12, 560-567.	0.7	25
101	Ticagrelor Improves Endothelial Function by Decreasing Circulating Epidermal Growth Factor (EGF). Frontiers in Physiology, 2018, 9, 337.	1.3	25
102	Does the site of bleeding matter? A stratified analysis on Flocation of TIMI-graded bleedings and their impact on 12-month outcome in patients with ST-segment elevation myocardial infarction. EuroIntervention, 2012, 8, 71-78.	1.4	25
103	Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end pointsâ€"Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). American Heart Journal, 2018, 198, 152-159.	1.2	24
104	Functional assessment of coronary stenosis: an overview of available techniques. Is quantitative flow ratio a step to the future?. Expert Review of Cardiovascular Therapy, 2018, 16, 951-962.	0.6	24
105	Physiology-guided revascularization versus optimal medical therapy of nonculprit lesions in elderly patients with myocardial infarction: Rationale and design of the FIRE trial. American Heart Journal, 2020, 229, 100-109.	1.2	24
106	Coronary Microvascular Dysfunction: PET, CMR and CT Assessment. Journal of Clinical Medicine, 2021, 10, 1848.	1.0	24
107	Impact of COVID-19 pandemic and infection on in hospital survival for patients presenting with acute coronary syndromes: A multicenter registry. International Journal of Cardiology, 2021, 332, 227-234.	0.8	24
108	Impairment of mitophagy and autophagy accompanies calcific aortic valve stenosis favouring cell death and the severity of disease. Cardiovascular Research, 2022, 118, 2548-2559.	1.8	24

#	Article	IF	Citations
109	Pro-inflammatory genetic profile and familiarity of acute myocardial infarction. Immunity and Ageing, 2012, 9, 14.	1.8	23
110	Thrombin generation assay. Blood Coagulation and Fibrinolysis, 2012, 23, 680-687.	0.5	22
111	Coagulation Factors and Recurrence of Ischemic and Bleeding Adverse Events in Patients with Acute Coronary Syndromes. Thrombosis Research, 2013, 132, 151-157.	0.8	22
112	A Prospective Evaluation of a Pre-Specified Absorb BVS Implantation Strategy in ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2017, 10, 1855-1864.	1.1	22
113	Predicting return to work after acute myocardial infarction: Socio-occupational factors overcome clinical conditions. PLoS ONE, 2018, 13, e0208842.	1.1	22
114	Physical activity intervention for elderly patients with reduced physical performance after acute coronary syndrome (HULK study): rationale and design of a randomized clinical trial. BMC Cardiovascular Disorders, 2018, 18, 98.	0.7	22
115	Post-Procedural Bivalirudin Infusion atÂFull or Low Regimen in Patients WithÂAcute Coronary Syndrome. Journal of the American College of Cardiology, 2019, 73, 758-774.	1.2	22
116	Impact of postdilatation on performance of bioresorbable vascular scaffolds in patients with acute coronary syndrome compared with everolimus-eluting stents: A propensity score-matched analysis from a multicenter â€œreal-worldâ€•registry. Cardiology Journal, 2016, 23, 374-383.	0.5	22
117	The in vitro effects of verbascoside on human platelet aggregation. Journal of Thrombosis and Thrombolysis, 2012, 34, 318-325.	1.0	21
118	Clinical benefit of drugs targeting mitochondrial function as an adjunct to reperfusion in ST-segment elevation myocardial infarction: A meta-analysis of randomized clinical trials. International Journal of Cardiology, 2017, 244, 59-66.	0.8	21
119	Relationship between physical activity and long-term outcomes in patients with stable coronary artery disease. European Journal of Preventive Cardiology, 2020, 27, 426-436.	0.8	21
120	Invasive Coronary Physiology After StentÂImplantation. JACC: Cardiovascular Interventions, 2021, 14, 237-246.	1.1	21
121	A naturally occurring mutation in ATP synthase subunit c is associated with increased damage following hypoxia/reoxygenation in STEMI patients. Cell Reports, 2021, 35, 108983.	2.9	21
122	Impact of Body Mass Index on 5-Year Clinical Outcomes in Patients With STâ€“Segment Elevation Myocardial Infarction After Everolimus-Eluting or Bare-Metal Stent Implantation. American Journal of Cardiology, 2017, 120, 1460-1466.	0.7	20
123	Ticagrelor Increases SIRT1 and HES1 mRNA Levels in Peripheral Blood Cells from Patients with Stable Coronary Artery Disease and Chronic Obstructive Pulmonary Disease. International Journal of Molecular Sciences, 2020, 21, 1576.	1.8	20
124	Optical coherence tomography, intravascular ultrasound or angiography guidance for distal left main coronary stenting. The <scp>ROCK</scp> cohort <scp>II</scp> study. Catheterization and Cardiovascular Interventions, 2022, 99, 664-673.	0.7	20
125	Frailty in patients admitted to hospital for acute coronary syndrome: when, how and why?. Journal of Geriatric Cardiology, 2019, 16, 129-137.	0.2	20
126	Long-term outcome after drug eluting stenting in patients with ST-segment Elevation Myocardial Infarction. International Journal of Cardiology, 2010, 140, 154-160.	0.8	19

#	Article	IF	Citations
127	The frailty in elderly patients receiving cardiac interventional procedures (FRASER) program: rational and design of a multicenter prospective study. Aging Clinical and Experimental Research, 2017, 29, 895-903.	1.4	19
128	Reproducibility of quantitative flow ratio: the QREP study. EuroIntervention, 2022, 17, 1252-1259.	1.4	19
129	Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: Rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor Sprint stent in Uncertain DES Candidates study. American Heart Journal, 2013, 166, 831-838.	1.2	18
130	Safety and Feasibility of Transradial Mini-Invasive Balloon Aortic Valvuloplasty. JACC: Cardiovascular Interventions, 2017, 10, 1375-1377.	1.1	18
131	Coronary calcium score as a predictor of outcomes in the hypertensive Covid-19 population: results from the Italian (S) Core-Covid-19 Registry. Hypertension Research, 2022, 45, 333-343.	1.5	18
132	Predischarge screening for chronic obstructive pulmonary disease in patients with acute coronary syndrome and smoking history. International Journal of Cardiology, 2016, 222, 806-812.	0.8	17
133	Right anterior mini-thoracotomy vs. conventional sternotomy for aortic valve replacement: a propensity-matched comparison. Journal of Thoracic Disease, 2018, 10, 1588-1595.	0.6	17
134	Limb salvage in diabetic patients with no-option critical limb ischemia: outcomes of a specialized center experience. Diabetic Foot & Ankle, 2019, 10, 1696012.	2.8	17
135	Comparison of quantitative flow ratio, Pd/Pa and diastolic <scp>hyperemiaâ€free</scp> ratio versus fractional flow reserve in <scp>nonâ€culprit</scp> lesion of patients with non <scp>ST</scp>â€segment elevation myocardial infarction. Catheterization and Cardiovascular Interventions, 2021, 98, 1057-1065.	0.7	17
136	Angio-Based Fractional Flow Reserve, Functional Pattern of Coronary Artery Disease, and Prediction of Percutaneous Coronary Intervention Result: a Proof-of-Concept Study. Cardiovascular Drugs and Therapy, 2022, 36, 645-653.	1.3	17
137	Increased sHLA-G Is Associated with Improved COVID-19 Outcome and Reduced Neutrophil Adhesion. Viruses, 2021, 13, 1855.	1.5	17
138	Safety and Long-Term Efficacy of Sirolimus Eluting Stent in ST-elevation Acute Myocardial Infarction: The REAL (Registro REgionale AngiopLastiche Emilia-Romagna) Registry. Cardiovascular Drugs and Therapy, 2006, 20, 63-68.	1.3	16
139	Evaluation of Platelet Inhibition by Tirofiban in Patients Stratified According to Aspirin and Clopidogrel Responsiveness. Journal of the American College of Cardiology, 2010, 55, 255-256.	1.2	16
140	CHA2DS2â€VASc score predicts atrial fibrillation recurrence after cardioversion: Systematic review and individual patient pooled metaâ€analysis. Clinical Cardiology, 2019, 42, 358-364.	0.7	16
141	Translating Evidence from Clonal Hematopoiesis to Cardiovascular Disease: A Systematic Review. Journal of Clinical Medicine, 2020, 9, 2480.	1.0	16
142	The hidden interplay between sex and COVID-19 mortality: the role of cardiovascular calcification. GeroScience, 2021, 43, 2215-2229.	2.1	16
143	High-Dose BoluS TiRofibAn and Sirolimus Eluting STEnt versus Abiciximab and Bare Metal Stent in Acute MYocardial Infarction (STRATEGY) Studyâ€”Protocol Design and Demography of the First 100 Patients. Cardiovascular Drugs and Therapy, 2004, 18, 225-230.	1.3	15
144	Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction. American Heart Journal, 2007, 154, 39-45.	1.2	15

#	Article	IF	Citations
145	Bioresorbable vascular scaffold overlap evaluation with optical coherence tomography after implantation with or without enhanced stent visualization system (WOLFIE study): a two-centre prospective comparison. International Journal of Cardiovascular Imaging, 2016, 32, 211-223.	0.7	15
146	Safety of FFR-guided revascularisation deferral in Anatomically prognostiC diseasE (FACE:) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 707 Td 270, 107-112.	0.8	15
147	Cost-effectiveness of the coronary sinus Reducer and its impact on the healthcare burden of refractory angina patients. European Heart Journal Quality of Care & Clinical Outcomes, 2020, 6, 32-40.	1.8	15
148	Adding a â€œNotchâ€•to Cardiovascular Disease Therapeutics: A MicroRNA-Based Approach. Frontiers in Cell and Developmental Biology, 2021, 9, 695114.	1.8	15
149	Seven french radial artery access for PCI: A prospective single-center experience. International Journal of Cardiology, 2014, 176, 1074-1075.	0.8	14
150	Fractional flow reserve implementation in daily clinical practice: A European survey. International Journal of Cardiology, 2016, 207, 206-207.	0.8	14
151	P2Y12 inhibitors monotherapy after short course of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials including 29â€‰089 patients. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 196-205.	1.4	14
152	Sex-specific benefits of sirolimus-eluting stent on long-term outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Insights from the Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study trial. American Heart Journal, 2012, 163, 104-111.	1.2	13
153	Optical coherence tomography evaluation of overlapping everolimus-eluting bioresorbable vascular scaffold implantation guided by enhanced stent visualization system. International Journal of Cardiology, 2015, 182, 1-3.	0.8	13
154	Data on administration of cyclosporine, nicorandil, metoprolol on reperfusion related outcomes in ST-segment Elevation Myocardial Infarction treated with percutaneous coronary intervention. Data in Brief, 2017, 14, 197-205.	0.5	13
155	Effectiveness of a Novel Nutraceutical Compound Containing Red Yeast Rice, Polymethoxyflavones and Antioxidants in the Modulation of Cholesterol Levels in Subjects With Hypercholesterolemia and Low-Moderate Cardiovascular Risk: The NIRVANA Study. Frontiers in Physiology, 2019, 10, 217.	1.3	13
156	Safety, efficacy and impact on frailty of mini-invasive radial balloon aortic valvuloplasty. Heart, 2021, 107, 874-880.	1.2	13
157	Specific and selective If inhibition: expected clinical benefits from pure heart rate reduction in coronary patients. Country Review Ukraine, 2005, 7, H16-H21.	0.8	12
158	Different clinical models of CD34Â+Âcells mobilization in patients with cardiovascular disease. Journal of Thrombosis and Thrombolysis, 2011, 32, 1-8.	1.0	12
159	Incidence and Outcome of High On-Treatment Platelet Reactivity in Patients With Non-ST Elevation Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the VIP) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T 792-798.	0.7	12
160	Enhanced stent visualization systems during PCI: A case series and review of literature. Journal of Cardiology Cases, 2015, 12, 1-5.	0.2	12
161	CHA₂DS₂-VASc risk factors as predictors of stroke after acute coronary syndrome: A systematic review and meta-analysis. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 264-274.	0.4	12
162	Inhaled corticosteroid/long-acting bronchodilator treatment mitigates STEMI clinical presentation in COPD patients. European Journal of Internal Medicine, 2018, 47, 82-86.	1.0	12

#	Article	IF	Citations
163	Efficacy and safety of alternative oral administrations of P2Y12â€receptor inhibitors: Systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2019, 17, 944-950.	1.9	12
164	Long-term effects of coronavirus disease 2019 on the cardiovascular system, CV COVID registry: A structured summary of a study protocol. PLoS ONE, 2021, 16, e0255263.	1.1	12
165	A counseling program on nuisance bleeding improves quality of life in patients on dual antiplatelet therapy: A randomized controlled trial. PLoS ONE, 2017, 12, e0182124.	1.1	12
166	Bleeding Risk Scores and Scales of Frailty for the Prediction of Haemorrhagic Events in Older Adults with Acute Coronary Syndrome: Insights from the FRASER study. Cardiovascular Drugs and Therapy, 2019, 33, 523-532.	1.3	11
167	Sirolimus-Eluting Magnesium Resorbable Scaffold Implantation in Patients with Acute Myocardial Infarction. Cardiology, 2019, 142, 93-96.	0.6	11
168	Development, optimization and validation of an absolute specific assay for active myeloperoxidase (MPO) and its application in a clinical context: role of MPO specific activity in coronary artery disease. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1749-1758.	1.4	11
169	Methylation of SERPINA1 gene promoter may predict chronic obstructive pulmonary disease in patients affected by acute coronary syndrome. Clinical Epigenetics, 2021, 13, 79.	1.8	11
170	Patient selection to enhance the long-term benefit of first generation drug-eluting stents for coronary revascularisation procedures. Insights from a large multicentre registry. EuroIntervention, 2009, 5, 57-66.	1.4	11
171	Impact of a recent hospitalization on treatment and prognosis of ST-segment elevation myocardial infarction. International Journal of Cardiology, 2013, 167, 296-297.	0.8	10
172	Dual Antiplatelet Therapy in Patients with Glucose-6-Phosphate Dehydrogenase Deficiency undergoing PCI with Drug-Eluting Stents. Journal of Atherosclerosis and Thrombosis, 2015, 22, 535-541.	0.9	10
173	Same-day transfer for the invasive strategy of patients with non-ST-segment elevation acute coronary syndrome admitted to spoke hospitals: Data from the Emilia-Romagna Regional Network. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 428-434.	0.4	10
174	Are acute coronary syndromes an ideal scenario for bioresorbable vascular scaffold implantation?. Journal of Thoracic Disease, 2017, 9, S969-S978.	0.6	10
175	Role of ST-Segment Resolution in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention (from the 5-Year Outcomes of the EXAMINATION) Tj ETQq1 1 0.784314 rgBT /Over Cardiology, 2018, 121, 1039-1045.	0.7	10
176	Snuffbox approach for balloon aortic valvuloplasty: A case series. Catheterization and Cardiovascular Interventions, 2021, 97, E743-E747.	0.7	10
177	Relevance of gender in patients with acute myocardial infarction undergoing coronary interventions. Journal of Cardiovascular Medicine, 2013, 14, 421-429.	0.6	9
178	A prospective evaluation of a standardized strategy for the use of a polymeric everolimusâ€eluting bioresorbable scaffold in STâ€segment elevation myocardial infarction: Rationale and design of the BVS STEMI STRATEGYâ€IT study. Catheterization and Cardiovascular Interventions, 2017, 89, 1129-1138.	0.7	9
179	Long-term clinical outcomes and cost-effectiveness analysis in multivessel percutaneous coronary interventions: comparison of drug-eluting stents, bare-metal stents and a mixed approach in patients at high and low risk of repeat revascularisation. EuroIntervention, 2010, 5, 953-961.	1.4	9
180	The Underestimated Role of Platelets in Severe Infection a Narrative Review. Cells, 2022, 11, 424.	1.8	9

#	Article	IF	Citations
181	Latest Clinical Data on Testing for High On-Treatment Platelet Reactivity. Reviews in Cardiovascular Medicine, 2011, 12, 14-22.	0.5	9
182	Abciximab: a reappraisal of its use in coronary care. Biologics: Targets and Therapy, 2008, 2, 29.	3.0	8
183	Effectiveness and safety of the ABSORB bioresorbable vascular scaffold for the treatment of coronary artery disease: systematic review and meta-analysis of randomized clinical trials. Journal of Thoracic Disease, 2017, 9, S887-S897.	0.6	8
184	COX-2 Is Downregulated in Human Stenotic Aortic Valves and Its Inhibition Promotes Dystrophic Calcification. International Journal of Molecular Sciences, 2020, 21, 8917.	1.8	8
185	Contrast Associated Acute Kidney Injury and Mortality in Older Adults with Acute Coronary Syndrome: A Pooled Analysis of the FRASER and HULK Studies. Journal of Clinical Medicine, 2021, 10, 2151.	1.0	8
186	Management of aspirin intolerance in patients undergoing percutaneous coronary intervention. The role of mono-antiplatelet therapy: a retrospective, multicenter, study. Minerva Cardioangiologica, 2019, 67, 94-101.	1.2	8
187	Impact of stent overlapping on long-term clinical outcomes in patients with ST-segment elevation myocardial infarction: insights from the five-year follow-up of the EXAMINATION trial. EuroIntervention, 2017, 13, e557-e563.	1.4	8
188	Two-year outcomes after first- or second-generation drug-eluting stent implantation in patients with in-stent restenosis. A PRODIGY trial substudy. International Journal of Cardiology, 2014, 173, 343-345.	0.8	7
189	Endothelial dysfunction and increased platelet reactivity in patients with acute coronary syndrome and undiagnosed COPD: insights into the SCAP trial. European Respiratory Journal, 2017, 50, 1701183.	3.1	7
190	Short term outcome following acute phase switch among P2Y12 inhibitors in patients presenting with acute coronary syndrome treated with PCI: A systematic review and meta-analysis including 22,500 patients from 14 studies. IJC Heart and Vasculature, 2019, 22, 39-45.	0.6	7
191	Impaired platelet reactivity in patients with septic shock: a proof-of-concept study. Platelets, 2020, 31, 652-660.	1.1	7
192	Adenosine-Free Indexes vs. Fractional Flow Reserve for Functional Assessment of Coronary Stenoses: Systematic Review and Meta-Analysis. International Journal of Cardiology, 2020, 299, 93-99.	0.8	7
193	Priorities for Cath labs in the COVID-19 tsunami. European Heart Journal, 2020, 41, 1784-1785.	1.0	7
194	Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and Rationale. Journal of Cardiovascular Translational Research, 2021, 14, 110-119.	1.1	7
195	Prospective Identification of Stent Fracture by Enhanced Stent Visualization System During Percutaneous Coronary Intervention. Circulation Journal, 2017, 81, 82-89.	0.7	7
196	Correlates of non-target vessel-related adverse events in patients with ST-segment elevation myocardial infarction: insights from five-year follow-up of the EXAMINATION trial. EuroIntervention, 2018, 13, 1939-1945.	1.4	7
197	Comparison of Verapamil versus Heparin as Adjunctive Treatment for Transradial Coronary Procedures: The VERMUT Study. Cardiology, 2018, 140, 74-82.	0.6	6
198	Does Large Vessel Size Justify Use of Bare-Metal Stents in Primary Percutaneous Coronary Intervention?. Circulation: Cardiovascular Interventions, 2019, 12, e007705.	1.4	6

#	Article	IF	Citations
199	One-Year Results Following a Pre-Specified ABSORB Implantation Strategy in ST-Elevation Myocardial Infarction (BVS STEMI STRATEGY-IT Study). Cardiovascular Revascularization Medicine, 2019, 20, 700-704.	0.3	6
200	Outcome of Coronary Ostial Stenting to Prevent Coronary Obstruction During Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2020, 13, e009017.	1.4	6
201	Lamin A/C Missense Mutation R216C Pinpoints Overlapping Features Between Brugada Syndrome and Laminopathies. Circulation Genomic and Precision Medicine, 2020, 13, e002751.	1.6	6
202	Italian Multicenter Registry of Bare Metal Stent Use in Modern Percutaneous Coronary Intervention Era (AMARCORD): A multicenter observational study. Catheterization and Cardiovascular Interventions, 2021, 97, 411-420.	0.7	6
203	Diastolic dysfunction, frailty and prognosis in elderly patients with acute coronary syndromes. International Journal of Cardiology, 2021, 327, 31-35.	0.8	6
204	Aortic stenosis, transcatheter aortic valve replacement and transthyretin cardiac amyloidosis: are we progressively unraveling the tangle?. European Journal of Heart Failure, 2021, 23, 259-263.	2.9	6
205	Tools for the Assessment of the Malnutrition Status and Possible Interventions in Elderly with Cardiovascular Diseases. Journal of Clinical Medicine, 2021, 10, 1508.	1.0	6
206	Acetylcholine Use in Modern Cardiac Catheterization Laboratories: A Systematic Review. Journal of Clinical Medicine, 2022, 11, 1129.	1.0	6
207	Tailored Medical and Interventional Therapy Against Recurrent Stent Thrombosis After Drug-Eluting Stenting. Clinical and Applied Thrombosis/Hemostasis, 2010, 16, 591-593.	0.7	5
208	Medical and interventional management of patients with severe thrombocytopenia undergoing percutaneous coronary intervention. Journal of Thrombosis and Haemostasis, 2012, 10, 153-156.	1.9	5
209	Factor XI rs2036914 gene polymorphism and occurrence of adverse events after percutaneous coronary intervention. A prospective evaluation. International Journal of Cardiology, 2014, 177, 711-713.	0.8	5
210	Impact of Culprit Plaque and Atherothrombotic Components on Incomplete Stent Apposition in Patients With ST-Elevation Myocardial Infarction Treated With Everolimus-Eluting Stentsã€€â€“ An OCTAVIA Substudy â€“. Circulation Journal, 2016, 80, 895-905.	0.7	5
211	Pharmacological protection of reperfusion injury in ST-segment elevation myocardial infarction. Gone with the wind?. Postepy W Kardiologii Interwencyjnej, 2018, 14, 5-8.	0.1	5
212	Longâ€term impact of diabetes in patients with STâ€segment elevation myocardial infarction: Insights from the EXAMINATION randomized trial. Catheterization and Cardiovascular Interventions, 2019, 94, 917-925.	0.7	5
213	Peak atrial longitudinal strain is predictive of atrial fibrillation in patients with chronic obstructive pulmonary disease and coronary artery disease. Echocardiography, 2021, 38, 909-915.	0.3	5
214	Clinical governance programme in patients with acute coronary syndrome: design and methodology of a quality improvement initiative. Open Heart, 2020, 7, e001415.	0.9	5
215	Long-term outcomes with cobalt-chromium bare-metal vs. drug-eluting stents: the REgistro regionale AngiopLastiche dell'Emilia-Romagna registry. Journal of Cardiovascular Medicine, 2011, 12, 102-109.	0.6	4
216	Right Ventricle Function in Patients with Acute Coronary Syndrome and Concomitant Undiagnosed Chronic Obstructive Pulmonary Disease. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2019, 16, 284-291.	0.7	4

#	Article	IF	Citations
217	Influenza coverage rates in subjects with chronic heart diseases: results obtained in four consecutive immunisation seasons in the Local Health Unit of Ferrara (North Italy)â€. Archives of Public Health, 2020, 78, 103.	1.0	4
218	Is pleural effusion in COVID-19 interstitial pneumonia related to in-hospital mortality?. Italian Journal of Medicine, 2021, 15, .	0.2	4
219	Quantitative flow ratio as a new tool for angiography-based physiological evaluation of coronary artery disease: a review. Future Cardiology, 2021, 17, 1435-1452.	0.5	4
220	Physical performance status predicts mortality in aging patients undergoing pacemaker implantation. Journal of Cardiovascular Medicine, 2021, 22, 738-743.	0.6	4
221	Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 1170-1179.	0.4	4
222	Impact of Absorb bioresorbable scaffold implantation technique on post-procedural quantitative coronary angiographic endpoints in ST-elevation myocardial infarction: a sub-analysis of the BVS STEMI STRATEGY-IT study. EuroIntervention, 2019, 15, 108-115.	1.4	4
223	Bioresorbable scaffolds versus everolimus-eluting metallic stents: five-year clinical outcomes of the randomised ABSORB II trial. EuroIntervention, 2020, 16, e938-e941.	1.4	4
224	The impact of sex and physical performance on long-term mortality in older patients with myocardial infarction. BMC Medicine, 2022, 20, 15.	2.3	4
225	Procalcitonin Predicts Bacterial Infection, but Not Long-Term Occurrence of Adverse Events in Patients with Acute Coronary Syndrome. Journal of Clinical Medicine, 2022, 11, 554.	1.0	4
226	Complete versus culpritâ€only strategy in older MI patients with multivessel disease. Catheterization and Cardiovascular Interventions, 2022, 99, 970-978.	0.7	4
227	Temporal and Genotype-Driven Variation of Factor VII Levels in Patients With Acute Myocardial Infarction. Clinical and Applied Thrombosis/Hemostasis, 2009, 15, 119-122.	0.7	3
228	Kounisâ€“Zavras syndrome presenting with ventricular arrhythmias and cardiogenic shock. Journal of Cardiology Cases, 2013, 7, e74-e77.	0.2	3
229	The Mitochondrial Permeability Transition Pore. , 2018, , 47-73.		3
230	Cost-effectiveness of everolimus-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: An analysis from the EXAMINATION randomized controlled trial. PLoS ONE, 2018, 13, e0201985.	1.1	3
231	Reply-Letter to the Editor-Nutritional status and all cause mortality in older adults with acute coronary syndrome. Clinical Nutrition, 2019, 38, 2956-2957.	2.3	3
232	Current evidence on the diagnostic and prognostic role of native T1 mapping in heart diseases. Trends in Cardiovascular Medicine, 2020, 31, 448-454.	2.3	3
233	Phenotypic heterogeneity of COVIDâ€19 pneumonia: clinical and pathophysiological relevance of the vascular phenotype^a. ESC Heart Failure, 2022, 9, 263-269.	1.4	3
234	Promotion and maintenance of physically active lifestyle in older outpatients 2 years after acute coronary syndrome. Aging Clinical and Experimental Research, 2022, 34, 1065-1072.	1.4	3

#	Article	IF	Citations
235	Tirofiban: a critical reappraisal of the clinical use, recent developments and future perspectives. Future Cardiology, 2006, 2, 17-27.	0.5	2
236	Boosting platelet inhibition in poor responder to aspirin and clopidogrel undergoing percutaneous coronary intervention: role of tirofiban. Journal of Blood Medicine, 2010, 1, 61.	0.7	2
237	BRS implantation in long lesions requiring device overlapping: myth or reality?. Journal of Thoracic Disease, 2017, 9, S914-S922.	0.6	2
238	Impact of angiographic coronary artery disease complexity on ischemic and bleeding risks and on the comparative effectiveness of zotarolimus-eluting vs. bare-metal stents in uncertain drug-eluting stent candidates. International Journal of Cardiology, 2019, 277, 60-65.	0.8	2
239	Concealed SARS-CoV-2 interstitial pneumonia unmasked by infarct-like acute myocarditis. European Heart Journal - Case Reports, 2020, 4, 1-2.	0.3	2
240	Anatomical and functional healing after resorbable magnesium scaffold implantation in human coronary vessels: A combined optical coherence tomography and quantitative flow ratio analysis. Catheterization and Cardiovascular Interventions, 2021, 98, 1038-1046.	0.7	2
241	Beta-blockers and COPD: how can harmony be restored in a marriage in crisis?. European Heart Journal, 2020, 41, 4423-4424.	1.0	2
242	Moving forward from statistical to clinical considerations regarding complete revascularization. European Heart Journal, 2020, 41, 2225-2225.	1.0	2
243	Index of microcirculatory resistance assessment in patients with new diagnosis of left ventricular dilatation without significant coronary artery lesions: IMPAIRED pilot trial. European Journal of Heart Failure, 2020, 22, 561-563.	2.9	2
244	Similarities between fibroblasts and cardiomyocytes in the study of the permeability transition pore. European Journal of Clinical Investigation, 2022, 52, e13764.	1.7	2
245	Ticagrelor and Endothelial Function: An Effect That Persists Far From the Acute Phase and in Monotherapy. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 799-801.	1.1	2
246	New and old strategies to afford the liberal use of drug-eluting stents in real-life scenarios. Country Review Ukraine, 2005, 7, K31-K35.	0.8	1
247	A strategy to offset the extra cost of sirolimus-eluting stent in patients undergoing intervention for acute myocardial infarction. International Journal of Cardiology, 2008, 128, 53-61.	0.8	1
248	Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions. JACC: Cardiovascular Interventions, 2017, 10, 1274-1275.	1.1	1
249	Resting distal to aortic pressure ratio and fractional flow reserve discordance affects the diagnostic performance of quantitative flow ratio: Results from an individual patient data metaâ€analysis. Catheterization and Cardiovascular Interventions, 2021, 97, 825-832.	0.7	1
250	Drug-eluting stents: new presumed effects over in-stent restenosis prevention. Minerva Cardiology and Angiology, 2021, 69, 141-143.	0.4	1
251	Angiographic control versus ischaemia-driven management of patients undergoing percutaneous revascularisation of the unprotected left main coronary artery with second-generation drug-eluting stents: rationale and design of the PULSE trial. Open Heart, 2020, 7, e001253.	0.9	1
252	Gender differences in acute coronary syndromes patterns during the COVID-19 outbreak. American Journal of Cardiovascular Disease, 2020, 10, 506-513.	0.5	1

#	Article	IF	Citations
253	Three-year results of ST-segment elevation myocardial infarction patients treated with a prespecified bioresorbable vascular scaffold implantation strategy: bVS STEMI STRATEGY-IT long-term. Journal of Cardiovascular Medicine, 2022, 23, 278-280.	0.6	1
254	The unbearable lightness of the instantaneous wave-free ratio/fractional flow reserve discordance. Journal of Cardiovascular Medicine, 2022, 23, 116-118.	0.6	1
255	Angiography-derived physiology guidance vs usual care in an All-comers PCI population treated with the healing-targeted supreme stent and Ticagrelor monotherapy: PIONEER IV trial design. American Heart Journal, 2022, 246, 32-43.	1.2	1
256	Lipid plaque burden in NSTE-ACS patients with or without COPD: insights from the SCAP Trial. Minerva Cardiology and Angiology, 2021, 69, 738-745.	0.4	1
257	Role of Quantitative Flow Ratio in Predicting Future Cardiac Allograft Vasculopathy in Heart Transplant Recipients. Circulation: Cardiovascular Interventions, 2022, 15, e011656.	1.4	1
258	Response to Letter Regarding Article, â€œIntensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention: Results From the Double-Blind, Prospective, Randomized Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel Studyâ€. Circulation, 2010, 121, .	1.6	0
259	Operator, Drug or Device: Who Will Break Down Acute Stent Thrombosis?. Cardiology, 2017, 137, 244-245.	0.6	0
260	Meta-Analyses on DAPT Length. Journal of the American College of Cardiology, 2017, 70, 1303-1304.	1.2	0
261	Stent and Dual Antiplatelet Therapy Duration Comparisons in the Setting of a Multicenter Randomized Controlled Trial: Can the Operator Experience Affect the Study Results?. Journal of the American Heart Association, 2017, 6, .	1.6	0
262	Bioresorbable coronary scaffolds in 2017. Journal of Thoracic Disease, 2017, 9, S886-S886.	0.6	0
263	The authors reply. Critical Care Medicine, 2018, 46, e823.	0.4	0
264	Functional Assessment and Acute Coronary Syndrome. JACC: Cardiovascular Interventions, 2018, 11, 2433-2434.	1.1	0
265	A New Risk Chart of Acute Myocardial Infarction in Men by an Innovative Algorithm: A Pilot Study. Current Pharmacogenomics and Personalized Medicine, 2015, 12, 159-166.	0.2	0
266	The impact of the 3-year ABSORB II trial results on my clinical practice: an Italian survey. Journal of Thoracic Disease, 2017, 9, S898-S902.	0.6	0
267	How the functional assessment of culprit and non-culprit lesions may improve stratification and treatment of STEMI patients. Minerva Cardiology and Angiology, 2018, 66, 442-451.	0.4	0
268	Functional assessment 3.0: from wire through angio to OCT. EuroIntervention, 2020, 16, 534-535.	1.4	0
269	A Therapeutic Pathway in Patients with Chronic Coronary Syndromes: Proposal for Optimization. Journal of Clinical Medicine, 2022, 11, 2091.	1.0	0
270	IN-HOSPITAL antithrombotic therapy and outcomes of ELDERLY patients on warfarin undergoing percutaneous coronary intervention: Insights from the WAR-STENT registry. Indian Heart Journal, 2022, , .	0.2	0